In the last trading session, 1.68 million shares of the Galectin Therapeutics Inc (NASDAQ:GALT) were traded, and its beta was 0.71. Most recently the company’s share price was $1.90, and it changed around -$0.15 or -6.85% from the last close, which brings the market valuation of the company to $115.31M. GALT currently trades at a discount to its 52-week high of $4.27, offering almost -124.74% off that amount. The share price’s 52-week low was $1.55, which indicates that the current value has risen by an impressive 18.42% since then. We note from Galectin Therapeutics Inc’s average daily trading volume that its 10-day average is 0.43 million shares, with the 3-month average coming to 184.55K.
Galectin Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended GALT as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Galectin Therapeutics Inc is expected to report earnings per share of 0 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Galectin Therapeutics Inc (NASDAQ:GALT) trade information
Instantly GALT has showed a red trend with a performance of -6.85% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.81 on recent trading dayincreased the stock’s daily price by 32.38%. The company’s shares are currently up 14.76% year-to-date, but still down -31.96% over the last five days. On the other hand, Galectin Therapeutics Inc (NASDAQ:GALT) is -32.92% down in the 30-day period. We can see from the shorts that 5.52 million shares have been sold at a short interest cover period of 42.37 day(s).
Galectin Therapeutics Inc (GALT) estimates and forecasts
Galectin Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -29.70 percent over the past six months and at a 1.35% annual growth rate that is well below the industry average of 16.80%.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -14.30%.
GALT Dividends
Galectin Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Galectin Therapeutics Inc (NASDAQ:GALT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 30.95% of Galectin Therapeutics Inc shares, and 15.77% of them are in the hands of institutional investors. The stock currently has a share float of 22.85%. Galectin Therapeutics Inc stock is held by 101.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 3.4143% of the shares, which is about 2.12 million shares worth $4.78 million.
BLACKROCK INC., with 2.5232% or 1.56 million shares worth $3.53 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
